In 1949, the discovery of insulin-degrading enzyme (IDE), a protease that breaks down the B chain of the insulin hormone [8], prompted studies of the potential use of IDE inhibitors (IDEIs) to control insulin levels in animal models of diabetes. The gene discussed is INS; the disease is diabetes mellitus.